Combine cancer gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and Herpes simplex thymidine kinase suicide gene

Neoplasma

Volumn 53, Issue 5, 2006, Pages 353-362

  Pastorakova, A ^a   Hlubinova, K ^a   Jakubikova, J ^a   Altaner, C ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Apoptosis; Cancer gene therapy; Herpes simplex thymidine kinase; Retroviral vector; Tumor necrosis factor alpha

Indexed keywords

GANCICLOVIR; HERPES SIMPLEX THYMIDINE KINASE; HUMAN TUMOR NECROSIS FACTOR ALPHA; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CELL STRAIN MCF 7; DRUG ACTIVITY; DRUG MECHANISM; FLOW CYTOMETRY; GENE ACTIVITY; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GLIOMA; HERPES SIMPLEX; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; RETROVIRUS VECTOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUICIDE GENE; SUICIDE GENE THERAPY; VIRAL GENE THERAPY; WESTERN BLOTTING;

EID: 33750627141     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. BRIDGEWATER JA, SPRINGER CJ, KNOX RJ, MINTON NP. MICHAEL NP et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A: 2362-2370.
2. HLAVATY J, HLUBINOVA K, ALTANEROVA V, LISKA J, ALTANER C. Treatment of rat gliomas with recombinant retrovirus harboring Herpes simplex virus thymidine kinase suicide gene. Neoplasma 1997; 44: 342-347.
3. HLAVATY J, HLUBINOVA K, BIES J, ALTANER C. Cells producing recombinant retrovirus with thymidine kinase gene from Herpes simplex virus suitable for human cancer gene therapy. Neoplasma 1999; 46: 329-334.
4. KANAI F, SHIRATORI Y, YOSHIDA Y, WAKIMOTO H, HAMADA H et al. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 1996; 23: 1359-1368.
5. MANOME Y, WATANABE M, ABE T, TOMITA M, WATANABE S et al. Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor. Anticancer Res 2001; 21: 2265-2272.
6. MOOLTEN FL, WELLS JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
7. NICHOLAS TW, READ SB, BURROWS FJ, KRUSE CA. Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol Histopathol 2003; 18: 495-507.
8. PATTERSON AV, SAUNDERS MP, GRECO O. Prodrugs in genetic chemoradiotherapy. Curr Pharm Des 2003; 9: 2131-2154.
9. MANOME Y, WEN PY, DONG Y, TANAKA T, MITCHELL BS et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 1996; 2: 567-573.
10. SHIMIZU T, SHIMADA H, OCHIAI T, HAMADA H. Enhanced growth suppression in esophageal carcinoma cells using adenovirus-mediated fusion gene transfer (uracil phosphoribosyl transferase and herpes simplex virus thymidine kinase). Cancer Gene Ther 2001; 8: 512-521.
11. JOUNAIDI Y. Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic. Curr Drug Metab 2002; 3: 609-622.
12. ZHAN J, GAO Y, WANG W, SHEN A, ASPELUND A et al. Tumor-specific intravenous gene delivery using oncolytic adenoviruses. Cancer Gene Ther 2005; 12: 19-25.
13. DJEHA AH, HULME A, DEXTER MT, MOUNTAIN A, YOUNG LS et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 2000; 7: 721-731.
14. GREEN NK, YOUNGS DJ, NEOPTOLEMOS JP, FRIEDLOS F, KNOX RJ et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997; 4: 229-238.
15. OOSTERHOFF D, PINEDO HM, WITLOX MA, CARETTE JE, GERRITSEN WR et al. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. Gene Ther 2005; 12: 1011-1018.
16. PARKER WB, ALLAN PW, HASSAN AE, SECRIST JA III, SORSCHER EJ et al. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003; 10: 23-29.
17. PATTERSON AV, ZHANG H, MOGHADDAM A, BICKNELL R, TALBOT DC et al. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995; 72: 669-675.
18. MOOLTEN FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
19. BURROWS FJ, GORE M, SMILEY WR, KANEMITSU MY, JOLLY DJ et al. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther 2002; 9: 87-95.
20. FREEMAN SM, ABBOUD CN, WHARTENBY KA, PACKMAN CH, KOEPLIN DS et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
21. WU JK, CANO WG, MEYLAERTS SA, QI P, VRIONIS F et al. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 1994; 35: 1094-1102.
22. BAIS, DU L, LIU W, WHITTLE IR, HE L. Tentative novel mechanism of the bystander effect in glioma gene therapy with HSV-TK/GCV system. Biochem Biophys Res Commun 1999; 259: 455-459.
23. RAM Z, WALBRIDGE S, SHAWKER T, CULVER KW, BLAESE RM et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 1994; 81: 256-260.
24. KRUSE CA, LAMB C, HOGAN S, SMILEY WR, KLEINSCHMIDT-DEMASTERS BK et al. Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther 2000; 7: 118-127.
25. BARBA D, HARDIN J, SADELAIN M, GAGE FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 1994; 91: 4348-4352.
26. OKADA T, SHAH M, HIGGINBOTHAM JN, LI Q, WILDNER O et al. AV. TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Ther 2001; 8: 1315-1322.
27. SASAKI M, PLATE KH. Gene therapy of malignant glioma: recent advances in experimental and clinical studies. Ann Oncol 1998; 9: 1155-1166.
28. RAINOV NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-2401.
29. PALMER DH, YOUNG LS, MAUTNER V. Cancer gene-therapy: clinical trials. Trends Biotechnol 2006; 24: 76-82.
30. SANDMAIR AM, LOIMAS S, PURANEN P, IMMONEN A, KOSSILA M et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11: 2197-2205.
31. SHAND N, WEBER F, MARIANI L, BERNSTEIN M, GIANELLA-BORRADORI A et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999; 10: 2325-2335.
32. BELTINGER C, FULDA S, KAMMERTOENS T, MEYER E, UCKERT W et al. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci USA 1999; 96: 8699-8704.
33. TOMICIC MT, THUST R, KAINA B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 2002; 21: 2141-2153.
34. SUGARMAN BJ, AGGARWAL BB, HASS PE, FIGARI IS, PALLADINO MA, JR et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943-945.
35. CARSWELL EA, OLD LJ, KASSEL RL, GREEN S, FIORE N et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-3670.
36. KIRCHEIS R, WIGHTMAN L, KURSA M, OSTERMANN E, WAGNER E. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther 2002; 9: 731-735.
37. WATANABE N, NIITSU Y, UMENO H, KURIYAMA H, NEDA H et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48: 2179-2183.
38. VAN DE WIEL PA, BLOKSMA N, KUPER CF, HOFHUIS FM, WILLERS JM. Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity. J Pathol 1989; 157: 65-73.
39. BEUTLER B, VAN HC. Unraveling function in the TNF ligand and receptor families. Science 1994; 264: 667-668.
40. ROTHE J, GEHR G, LOETSCHER H, LESSLAUER W. Tumor necrosis factor receptors - structure and function. Immunol Res 1992; 11: 81-90.
41. SONG HY, REGNIER CH, KIRSCHNING CJ, GOEDDEL DV, ROTHE M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 1997; 94: 9792-9796.
42. WALLACH D, BOLDIN M, VARFOLOMEEV E, BEYAERT R, VANDENABEELE P et al. Cell death induction by receptors of the TNF faTNFmily: towards a molecular understanding. FEBS Lett 1997; 410: 96-106.
43. BRADHAM CA, QIAN T, STREETZ K, TRAUTWEIN C, BRENNER DA et al. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol 1998; 18: 6353-6364.
44. DENG Y, REN X, YANG L, LIN Y, WU X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003; 115: 61-70.
45. FUKUMURA D, SALEHI HA, WITWER B, TUMA RF, MELDER RJ et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 1995; 55: 4824-4829.
46. SCHMELZ K, WIEDER T, TAMMI, MULLER A, ESSMANN F et al. Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene 2004; 23: 6743-6759.
47. CHAWLA-SARKAR M, LINDNER DJ, LIU YF, WILLIAMS BR, SEN GC et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-249.
48. TARTAGLIA LA, WEBER RF, FIGARI IS, REYNOLDS C, PALLADINO MA, JR. et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991; 88: 9292-9296.
49. RUBY J, BLUETHMANN H, PESCHON JJ. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med 1997; 186: 1591-1596.
50. LAZDINS JK, GRELL M, WALKER MR, WOODS-COOK K, SCHEURICH P et al. Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells. J Exp Med 1997; 185: 81-90.
51. PINCKARD JK, SHEEHAN KC, SCHREIBER RD. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. J Biol Chem 1997; 272: 10784-10789.
52. PASTORAKOVA A, HLUBINOVA K, BODO J, LIBBY J, RYCHLY B et al. Tumor targeted gene therapy with plasmid expressing human tumor necrosis factor alpha in vitro and in vivo. Neoplasma 2005; 52: 344-351.
53. MORIUCHI S, OLIGINO T, KRISKY D, MARCONI P, FINK D et al. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res 1998; 58: 5731-5737.
54. NIRANJAN A, MORIUCHI S, LUNSFORD LD, KONDZIOLKA D, FLICKINGER JC et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2000; 2: 114-120.
55. NIRANJAN A, WOLFE D, TAMURA M, SOARES MK, KRISKY DM et al. Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 2003; 8: 530-542.
56. ZHANG JH, WAN MX, YUAN JY, PAN BR. Do there exist synergistic antitumor effects by coexpression of herpes simplex virus thymidine kinase with cytokine genes on human gastric cancer cell line SGC7901? World J Gastroenterol 2004; 10: 147-151.
57. OTSUKA G, NAGAYA T, SAITO K, MIZUNO M, YOSHIDA J et al. Inhibition of nuclear factor-kappaB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells. Cancer Res 1999; 59: 4446-4452.
58. CAI Z, KORNER M, TARANTINO N, CHOUAIB S. IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis. J Biol Chem 1997; 272: 96-101.
59. RATTER F, GASSNER C, SHATROV V, LEHMANN V. Modulation of tumor necrosis factor-alpha-mediated cytotoxicity by changes of the cellular methylation state: mechanism and in vivo relevance. Int Immunol 1999; 11: 519-527.